News

News

LiquiGlide Closes Intellectual Property-based Financing Deal in Collaboration with Aon and Atlas Credit Partners

LiquiGlide®, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, Aon plc (NYSE: AON), a leading global professional services firm, and Atlas Credit Partners, an asset management firm focused on value-oriented credit investments, today announced the completion of an intellectual-property based financing deal that provides LiquiGlide with $35 million to expand its commercial activities and continue to develop its platform for new applications.

4/22/2022

Verigraft | Safety assessment milestone reached in TECVI-1 clinical trial

Today VERIGRAFT announces that the company has successfully reached the safety assessment milestone in the first patient of the TECVI-1 clinical trial in which the safety of P-TEV for the treatment of CVI is investigated.

3/2/2022

Airbus to provide imagery services that enable Intelinair’s crop analytics platform

Intelinair and Airbus announced today a multi-year collaboration agreement that will provide high-resolution, Airbus satellite imagery as an input to Intelinair’s artificial intelligence (AI) powered crop analytics AGMRI® platform to deliver a complete view of every acre, every field from planting to harvest.

2/23/2022

Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson's Disease

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the conclusion of a randomized, placebo-controlled, double-blind Phase 2b (KARMET) study involving 150 patients with Parkinson’s Disease (PD).

1/27/2022

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of ZYNLONTA® (loncastuximab tesirine-lpyl) for all hematologic and solid tumor indications in Japan.

1/18/2022

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.

12/20/2021

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Marketing Authorization Application (MAA) for ZYNLONTA®, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the European Medicines Agency (EMA). Validation of the application enables the evaluation process by the EMA’s Committee for Medicinal Products for Human Use (CHMP) to begin.

10/29/2021

Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company.

10/7/2021

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma

Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed with ZYNLONTA®in a pivotal Phase 2 clinical trial in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in China.

9/29/2021

Drumroll Health Appoints New CEO and Members To Its Advisory Board

Pablo Graiver, founder and former CEO of Antidote, has joined Drumroll Health as its new Chief Executive Officer. The company also announced that industry veterans Paul Bleicher and Ritesh Patel have joined the Advisory Board, alongside Craig Lipset and Jennifer Levin Carter.

9/29/2021

Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations

9/27/2021

Intelinair Raises $20 Million in Series B to Expand Flagship Platform AGMRI

Intelinair has raised $20 million in Series B funding to continue to scale the company and its flagship crop intelligence platform, AGMRI®.

9/24/2021

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA®, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma (DLBCL).

9/13/2021

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).

8/26/2021

LiquiGlide Unveils Transformative Zero-Waste Packaging for the Health and Beauty Industry

LiquiGlide, the inventors of a breakthrough technology that is revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced the launch of zero-waste packaging for the health and beauty industry.

8/24/2021

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).

8/20/2021

Transparency Life Sciences Rebrands as Drumroll Health and Launches New AI-Powered Patient Insights Platform

Transparency Life Sciences, a digital health startup that develops technology solutions to foster closer partnerships between patients and health professionals, today unveiled a new corporate identity and company name: Drumroll Health.

8/10/2021

Humanity launches "slow your aging’" app in the UK and raises $2.5M more from health investors

The U.K.-based startup is clearly making waves amongst investors. It has now raised yet another seed funding round, this time totalling $2.5 million, from 65 health-tech and consumer-tech investors, taking its total raised to $5 million.

8/4/2021

Cibus and GDM Establish Strategic Partnership to Deliver New Solutions for Soybean Farmers

Cibus, a leader in precision gene editing in agriculture, and GDM, a leading global soybean research company, today announced a strategic collaboration focused on developing and delivering new solutions for challenges faced by soybean farmers.

7/7/2021

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

FibroGen, Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).

6/25/2021